No connection

Search Results

BNTX

BEARISH
$88.88 Live
BioNTech SE · NASDAQ
Target $131.94 (+48.4%)
$79.52 52W Range $124.0

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 01, 2026
Market cap
$22.34B
P/E
N/A
ROE
-5.9%
Profit margin
-39.6%
Debt/Equity
0.01
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
50%
BNTX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Concerns include weak profitability or high valuation.

Key Strengths

Low debt with D/E ratio of 0.01

Key Risks

Low profit margin of -39.6%
Weak financial trend (Piotroski F-Score: 2/9)
Declining revenue (-23.7%)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
30
Weak
Value
50
Future
35
Past
30
Health
35
Dividend
0
AI Verdict
BNTX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Concerns include weak profitability or high valuation.
Key drivers: Low debt with D/E ratio of 0.01, Low profit margin of -39.6%, Weak financial trend (Piotroski F-Score: 2/9)
Confidence
10%
Value
50/100

Rule-based valuation (P/E + Graham).

Positives
  • Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
35/100

Rule-based growth outlook.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • Revenue is contracting.
Past
30/100

Historical performance + price trend: Shares moved -20.9% over 5Y and -2.4% over 1Y.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • ROE only -5.9%.
  • Thin profit margins.
Health
35/100

Balance sheet & liquidity (Z-Score: N/A).

Positives
  • Low D/E ratio (0.01).
Watchpoints
No urgent risks highlighted.
Dividend
0/100

Dividend policy fallback.

Positives
  • Insufficient data for clear positives.
Watchpoints
  • No regular dividend payments.

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$88.88
Analyst Target
$131.94
Upside/Downside
+48.4%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for BNTX and closest competitors.

Updated 2026-03-31
BNT
BioNTech SE
Primary
5Y
-20.9%
3Y
-28.6%
1Y
-2.4%
6M
-9.9%
1M
-17.3%
1W
+2.4%
DGX
Quest Diagnostics Incorporated
Peer
5Y
+63.6%
3Y
+42.2%
1Y
+13.6%
6M
+8.7%
1M
+0.3%
1W
+0.6%
HUM
Humana Inc.
Peer
5Y
-54.8%
3Y
-63.9%
1Y
-31.8%
6M
-27.3%
1M
-4.6%
1W
+2.6%
CNC
Centene Corporation
Peer
5Y
-26.9%
3Y
-36.9%
1Y
-26.9%
6M
+31.2%
1M
+35.9%
1W
+13.6%
DXC
DexCom, Inc.
Peer
5Y
-31.7%
3Y
-50.1%
1Y
-22.2%
6M
-32.1%
1M
-11.2%
1W
+5.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-20.55
PEG Ratio
N/A
P/B Ratio
1.01
P/S Ratio
7.78
EV/Revenue
2.73
EV/EBITDA
-6.98
Market Cap
$22.34B

Profitability

Profit margins and return metrics

Profit Margin -39.59%
Operating Margin -33.35%
Gross Margin 78.7%
ROE -5.88%
ROA -3.56%

Growth

Revenue and earnings growth rates

Revenue Growth -23.7%
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.01
Low debt
Current Ratio
7.54
Strong
Quick Ratio
6.87
Excellent
Cash/Share
$57.26

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.9B
Gross Margin
63.3%
Op. Margin
-30.9%
Net Margin
-33.6%
Total Assets
$22.0B
Liabilities
$2.8B
Equity
$19.2B
Debt/Equity
0.14x
Operating CF
$0.3B
CapEx
$-0.1B
Free Cash Flow
$0.2B
FCF Yield
80%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-05
$N/A
2026-03-10
$-0.33
-30.4% surprise
2025-11-03
$-0.12
-220.3% surprise
2025-08-04
$-1.6
-13.8% surprise

Healthcare Sector Comparison

Comparing BNTX against 560 companies in the Healthcare sector (34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-5.88%
This Stock
vs
-88.14%
Sector Avg
-93.3% (Below Avg)
Profit Margin
-39.59%
This Stock
vs
-16.28%
Sector Avg
+143.2% (Superior)
Debt to Equity
0.01
This Stock
vs
2.66
Sector Avg
-99.5% (Less Debt)
Revenue Growth
-23.7%
This Stock
vs
124.04%
Sector Avg
-119.1% (Slower)
Current Ratio
7.54
This Stock
vs
4.47
Sector Avg
+68.5% (Stronger)

Similar Companies

Peer comparison within the same industry

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
18 analysts
HC Wainwright & Co.
2026-03-31
Maintains
Buy Buy
Morgan Stanley
2026-03-11
Maintains
Overweight Overweight
Canaccord Genuity
2026-03-11
Maintains
Buy Buy
Citigroup
2026-03-11
Maintains
Buy Buy
TD Cowen
2026-03-11
Maintains
Hold Hold
BMO Capital
2026-03-11
Maintains
Outperform Outperform
Jefferies
2026-03-10
Maintains
Buy Buy
Goldman Sachs
2026-01-16
up
Neutral Buy
HC Wainwright & Co.
2025-11-10
Maintains
Buy Buy
UBS
2025-11-06
Maintains
Neutral Neutral

Past News Coverage

Recent headlines mentioning BNTX from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI Chat
Markets
Profile